Algernon Pharmaceuticals Inc Class A (AGN)

CSE
11.150
+1.440(+14.83%)
  • Volume:
    25,713
  • Bid/Ask:
    10.810/11.150
  • Day's Range:
    10.050 - 11.900
  • Type:Equity
  • Market:Canada
  • ISIN:CA01559R4008
  • CUSIP:01559R400

AGN Overview

Prev. Close
9.71
Day's Range
10.05-11.9
Revenue
-
Open
10.05
52 wk Range
3.25-41
EPS
-5.26
Volume
25,713
Market Cap
18.67M
Dividend (Yield)
N/A
(N/A)
Average Volume (3m)
7,878
P/E Ratio
-
Beta
0.23
1-Year Change
-53.54%
Shares Outstanding
1,674,868
Next Earnings Date
-
What is your sentiment on Algernon Pharmaceuticals Inc Class A?
or
Market is currently closed. Voting is open during market hours.

Algernon Pharmaceuticals Inc Class A Company Profile

Employees
0
Market
Canada

Algernon Pharmaceuticals Inc. is a clinical stage pharmaceutical development company that is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough. The Company’s drug discovery approach is based on the concept of drug repurposing. Drug repurposing is the process of discovering new therapeutic uses for existing drugs. Its research and development (R&D) work are carried out by the Company’s Canadian subsidiary, Nash Pharmaceuticals Inc. (Nash Pharma). The Company’s lead compound is a drug called Ifenprodil, which is being developed for idiopathic pulmonary fibrosis (IPF) and chronic cough, as well as coronavirus disease of 2019 (COVID-19).

Read More

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyStrong BuyStrong BuyStrong BuySell
Technical IndicatorsStrong BuyStrong BuyStrong BuyStrong BuyStrong Sell
SummaryStrong BuyStrong BuyStrong BuyStrong BuyStrong Sell
  • Big news comin soon! Buckle up
    1
    • why we going down again?
      0
      • If you have already invested, then stay put.  Otherwise, it's a wait and see over the next 3 -6 months until positive results start moving towards some proven results which will ultimately lead to sales traction in various markets around the world.  No, a vaccine created in the UK, US or otherwise will not be the killer of ifenprodil treatments worldwide.  Expect to see above .50 and beyond for end of March of 2021.
        0
        • How about now?
          0
          • Anybody on the fence better load up now...
            0
            • Anybody on the fence better load up now...
              0
              • 09:30 Wed 05 Aug 2020Algernon says first patient dosed in Phase 2 study of Ifenprodil as a treatment in idiopathic pulmonary fibrosis and chronic cough
                2
                • Gonna pass 50 cents with new positive results soon
                  0
                  • This companies full of shit
                    4
                    • Algernon is starting to appear as a hidden gem among traditional BioTech 'buy and hope' purchases by the public.  Ifenprodil has been proven in the past, and is gaining more attention as a leading runner for 'treatment' of Covid-19 versus wishful thinking for a near term Vaccine/Cure.  Positive support for investigative trials in South Korea, Australia, Canada, and now the US is warming up as well.  Management has a strong position of awareness of the future outlook and complexities of the upcoming trials.  Minimum 6 month position recommended, with 12-18 months more realistic of expectations of turning a healthy return on your investment.  If you have the patience for the medium term, this could provide you with exceptional returns.
                      0
                      • How can they say they are cautioning that Ifenprodil is not expresing to treat covid 19 when they testing it to treat it....
                        0
                    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.